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Abstract
Background: The extent of angiogenesis seems to be an essential prognostic factor in many solid tumors of children and adults. Vascular 
endothelial growth factor (VEGF) is a proangiogenic cytokine that is highly expressed in many solid tumors often correlating with a poor 
prognosis.  Aim: The aim of the study was to assess the angiogenesis on the basis of serum VEGF levels and also to compare the concentrations 
in serum of carcinoma embryonic antigen, oxyproline, calcium and phosphorus in different types of bone tumors.  Patients and Methods: The 
research was conducted on 66 patients and also 22 healthy individuals, who were accepted to our clinic.  Patients were divided into three groups: 
primary bone cancer (n = 22), bone metastasis (n = 22), and benign bone tumors (n = 22).  Results: VEGF, CEA and oxyproline concentrations 
were increased in both primary bone tumors and bone metastasis in comparison with healthy individuals and patients with benign tumors 
(p < 0.05).  However, we found statistically significant higher phosphorus levels in all patient groups (p < 0.05), and higher calcium only in the 
bone metastasis group as compared with controls (p < 0.05).  A significant positive correlation existed between VEGF and CEA.  Conclusions: 
High VEGF levels, as a marker of angiogenesis, were associated with primary bone tumors and bone metastasis. The calcium and phosphorus 
content, in addition to VEGF, CEA and oxyproline levels, could be useful in prognosis and differentiation of the bone tumors.  Future studies in 
larger series are needed to confirm these data.
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Уровень сосудистого эндотелиального фактора роста, ракового эмбрионального антигена, кальция и фосфора в 
сыворотке крови при различных типах опухолей костей
Степень ангиогенеза представляется важным прогностическим фактором для многих солидных опухолей у детей и взрослых. 
Сосудистый эндотелиальный фактор роста (VEGF) является проангиогенным цитокином, который выявяается во многих солидных 
опухолях и часто приводит к отрицательным прогнозам.  Целью исследования была оценка ангиогенеза, основанная на определении в 
сыворотке крови уровня VEGF, а также сывороточных концентраций ракового эмбрионального антигена (РЭА), оксипролина, кальция 
и фосфата в различных типах костных опухолей.  В исследование было включено 66 больных, а также 22 здоровых человека.  Пациенты 
были разделены на три группы: с первичными костными опухолями (n = 22), с костными метастазами (n = 22) и с доброкачественными 
опухолями костей (n = 22).  Kонцентрация VEGF, РЭА и оксипролина в сыворотке крови пациентов с первичными и метастатическими 
опухолями костей была больше, в сравнении с показателями у контрольной группы и у больных с доброкачественными опухолями 
костей (р < 0,05).  Однако, мы обнаружили статистически значимое увеличение уровня фосфора во всех группах (р < 0,05), а кальция 
только у пациентов с костными метастазами по сравнению с контрольной группой (р < 0,05).  Существует значимая положительная 
корреляция между уровнями VEGF и РЭА.  B заключение необходимо отметить, что высокий уровень VEGF в качестве маркера 
ангиогенеза был выявлен в первичных опухолях костей и при костных метастазах.  Определение содержания кальция и фосфора, в 
дополнение к оценке уровней VEGF, РЭА и оксипролина, может оказаться полезным в оценке прогноза и дифференциации опухолей 
костей.
Ключевые слова: опухоль кости, ангиогенез, сосудистый эндотелиальный фактор роста, раковый эмбриональный антиген, 
оксипролин, кальций, фосфор.
Introduction
Bone cancer is an uncommon cancer type that begins in bone. 
Bone cancer can begin in any bone in the body, but most com-
monly it affects the long bones of the arms and legs [1].  Several 
types of bone cancer exist and some types of it occur primarily 
in children, while others affect mostly adults [1, 2].  The most 
common symptom of bone cancer is pain; other symptoms may 
vary depending on the location and size of the tumor [1].  The 
four most common types of primary bone cancer are: Multiple 
Myeloma, Osteosarcoma, Ewing’s sarcoma and Chondrosar-
coma.  There are also many types of benign bone tumors [1-3]. 
Primary bone cancer accounts for less than 0.2% of all cancers 
and approximately 1% of all diagnosed adult solid malignancies, 
although its incidence approaches 20% in pediatric cancers [2].
Bone metastasis are the tumors that begin elsewhere in the 
body and spread (metastasize) into the bone [1].  Breast, lung, 
and prostate cancers account for 80% of all bone metastasis [1, 
4].  Intractable pain and pathological fractures are the major 
complications of bone metastasis and can significantly affect 
the quality of life of the patients [1, 4].
The growth and dissemination of bone tumors de-
pend on angiogenesis [5].  There are many markers 
related to the tumor angiogenesis including vascular 
endothelial growth factor (VEGF).  It is a homodimeric 
heparin-binding protein (34-42 kDa), which induces 
formation of new blood vessels (angiogenesis) [6, 7]. 
VEGF-mediated capillary invasion is an essential signal 
that regulates growth plate morphogenesis and triggers 
cartilage remodeling [5].  Thus, VEGF is an essential 
coordinator of chondrocyte death, chondroclast func-
tion, extracellular matrix remodeling, angiogenesis and 
bone formation in the growth plate [6, 8].
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Carcinoma embryonic antigen (CEA) is one of the first 
tumor markers used in the monitoring patients with meta-
static disease during active therapy [9].  It is a glycoprotein 
which traditionally has been used to monitor gastrointestinal 
and breast malignancies [9].  However, an increasing CEA is 
a marker suggesting the failure of the treatment [10].
We aimed in this study to assess the angiogenesis by mea-
suring the level of serum VEGF and to compare the concen-
trations of serum CEA, oxyproline, calcium and phosphate 
in primary bone tumors, bone metastasis and benign bone 
tumors.
Material and methods
The subjects of the study were 66 patients admitted to the 
new oncology hospital of the Azerbaijan Medical University 
from May 2008 till December 2009.  The patients were divided 
into three experimental groups.  In the first group 22 patients 
with primary bone cancer were included, Osteosarcoma (n 
= 12), Ewing’s sarcoma (n = 8) and Chondrosarcoma (n = 
2).  Their age ranged from 11 to 46 years (mean, 18.8 years). 
In the second group 22 patients with bone metastasis were 
included, aged 42 to 61 years (mean, 51 years).  In the third 
group comprised 22 patients with benign bone tumors, aged 
11 to 51 years (mean, 19.2 years).  The control group included 
22 healthy volunteers.  Their age ranged from 18 to 56 years 
(mean, 22.8 years), see tab. 1.
Table 1
General characteristic  
of controls and bone cancer patients
Variables Cont-rols
Primary 
bone 
cancer
Bone  
meta-
stasis
Benign 
bone 
tumors
1. Total number (n) 22 22 22 22
2. Age in years (mean) 22.8 18.8 51 19.2
3. Sex:
Males 14 (64%) 14 (64%) 10 (45%) 15 (68%)
Females 8 (36%) 8 (36%) 12 (55%) 7 (22%)
Sample collection and preparation: Fasting blood 
samples (12 hours fasting) were collected from the patients 
and controls into test-tubes without additive and allowed to 
coagulate for 30 min.  Serum was obtained by centrifugation 
(1500 g) for 15 min at room temperature, and stored at −20º C.
Measurement of VEGF: Quantification of VEGF was per-
formed using commercial quantitative immunoassay kits for 
human VEGF (The IBL’s, Human VEGF ELISA kit; R&D syste-
ms, Germany). The amount of VEGF was expressed in pg/mL.
Measurement of CEA: CEA assay was done using com-
mercial quantitative immunoassay kits for human CEA, (The 
CEA ELISA kit; R&D systems, Germany).  Values of CEA were 
expressed in ng/mL.
Measurement of calcium and phosphorus: The determi-
nation of calcium and phosphate was performed using com-
mercial quantitative kits from Human Diagnostic (Germany), 
on HOSPITEX biochemical analyzer.
Measurement of oxyproline: The determination of 
oxyproline content was performed using colorimetry with 
dimethyl-aminobenzaldehyde after oxidation by chloramine 
B.  The absorbance was read at 550 nm.
Statistical Analysis: Statistical analysis was determined 
using STATGRAPHICS plus 5.1 statistical package software 
(STATPOINT TECHNOLOGIES, INC., USA) and Microsoft 
Excel.  The experimental data were expressed as mean ± stan-
dard deviation (SD).  The value of p < 0.05 was considered 
significant.
Results
Sixty-six patients with bone tumors were enrolled into 
this study.  A summary of descriptive statistics for the results 
of the serum levels of VEGF in the examined blood samples 
are presented in tab. 2.
Table 2 
Levels of serum VEGF in the examined blood samples of 
the patients with bone tumors and healthy controlsª
Parameter Controls(n = 22)
Primary
bone cancer
(n = 22)
Bone
metastasis
(n = 22)
Benign
bone tumors
(n = 22)
VEGF (pg/mL) 214.00 ± 41.7
698.22 ± 
72.1*,†
481.53 ± 
67.4*,§
230.23 ± 
34.6**
Minimum  63.41  307.32 281.19  77.23
Maximum 267.23 1205.21 825.30 294.76
ªValues are expressed as mean ± SD, 
* p < 0.05; ** p > 0.05; as compared with controls;
† p < 0.05; as compared with bone metastasis and/or benign 
bone tumors;
§ p < 0.05; as compared with primary bone cancer and/or 
benign bone tumors.
The results revealed that the levels of serum VEGF were 
significantly higher in both primary bone cancer and bone 
metastasis patient groups as compared with those of the 
controls (p < 0.05).  However, the difference between the 
levels of VEGF in the benign bone tumor patient group is not 
significant as compared with the control (p > 0.05).  Further-
more, the differences in VEGF levels between all investigated 
groups were significant (p < 0.05).  Thereby, the serum VEGF 
levels were higher as compared to controls in patients with 
primary bone cancer by 226.27% or 3.26 fold (p < 0.05), in 
patients with bone metastasis by125.01% or 2.25 fold (p < 
0.05) and in patients with benign bone tumors by 7.58% or 
1.08 fold (p > 0.05).  The serum VEGF levels in patients with 
primary bone cancer were higher as compared to the rest of 
the experimental groups.  In this group VEGF levels were 
higher by 45.0% or 1.45 fold (p < 0.05) than in patients with 
bone metastasis and by 203.27% or 3.03 fold (p < 0.05) than 
in patients with benign bone tumors (fig. 1).
The results of the assay of CEA serum levels in the exami-
ned blood samples are summarized in tab. 3.
The levels of serum CEA were found to be significantly 
higher in both primary bone cancer and bone metastasis pati-
ent groups than in those of the controls (p < 0.05).  However, 
there is no significant difference between the level of CEA 
in the patients with benign bone tumors as compared to the 
controls (p > 0.05).  Furthermore, there were significant di-
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Fig. 1.  Levels of serum VEGF in patients  
with bone tumors and healthy controls.
Fig. 2.  Levels of serum CEA in patients  
with bone tumors and healthy controls.
Fig. 3.  Levels of serum oxyproline, calcium and phosphorus in patients with bone tumors and healthy controls.
However, there was no significant difference between the 
oxyproline levels in the patients with benign bone tumors as 
compared to the controls (p > 0.05).  The levels of oxyproline 
were significantly lower in benign bone tumor patient group 
as compared with both primary bone cancer and bone me-
tastasis patient groups (p < 0.05).  Thus, the levels of serum 
oxyproline, as compared to the control levels, were higher in 
primary bone cancer patients by124.47% or 2.24 fold (p < 
0.05), in patients with bone metastasis by 94.86% or 1.95 fold 
Table 3
Levels of serum CEA in the examined blood samples for 
bone tumors patients and healthy controlsª
Parameter Controls  (n = 22)
Primary 
bone cancer
(n = 22)
Bone  
metastasis
(n = 22)
Benign  
bone tumors
(n = 22)
CEA (ng/mL) 1.42 ± 0.11 14.51 ± 3.13*
32.12 ± 
6.54*,† 1.7 1± 0.09**
Minimum 0.94  2.71 3.81  43.23
Maximum 2.18 29.87 62.77 294.76
ªValues are expressed as mean ± SD, 
* p < 0.05; as compared with controls; ** p >0.05; as compared 
with controls;
† p < 0.05; as compared with primary bone cancer and/or 
benign bone tumors.
fferences in CEA levels between all experimental groups (p 
< 0.05), see fig. 2.
The serum CEA levels as compared with the control 
values were higher in the patients with primary bone can-
cer by 921.83% or 10.22 fold (p < 0.05), in patients with 
bone metastasis by 2161.97% or 22.62 fold (p < 0.05), and 
inpatients with benign bone tumors by 20.42% or 1.2 fold 
(p > 0.05).
The serum calcium, phosphate and oxyproline levels in the 
examined blood samples are summarized in tab. 4.
The results revealed that the levels of oxyproline were 
significantly higher in primary bone cancer and bone me-
tastasis patients groups than those of the controls (p < 0.05). 
Table 4
Levels of oxyproline, calcium and phosphorus  
in the examined blood samples of the patients  
with bone tumors and healthy controlsª
Parameter Controls(n=22)
Primary 
bone cancer
(n=22)
Bone  
metastasis
(n=22)
Benign 
bone tumors 
(n=22)
Oxyproline  
(ng/mL)
Range 
122.6 ± 9.88
(112-163)
275.2 ± 
12.31*
(167-429)
238.9 ± 
10.54*
(134-340)
136.7 ± 
9.23**,†
(129-170)
Calcium  
(mg %) 
Range
8.13 ± 1.41
(7.8-8.9)
7.89 ± 1.25**
(7.2-8.7)
9.53 ± 1.43*
(8.2-10.1)
8.01 ± 1.19**
(7.4-9.0)
Phosphorus 
(mmol/L) 
Range
1.11 ± 0.19
(0.89-1.32)
1.63 ± 0.21*
(1.41-1.93)
1.57 ± 0.14*
(1.34-1.92)
1.69±0.31*
(1.44-1.95)
ª Values are expressed as mean ± SD; 
* p < 0.05; as compared with controls; ** p > 0.05; as compared 
with controls;
† p < 0.05; as compared with primary bone cancer and/or 
bone metastasis.
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(p < 0.05) and in patients with benign bone tumors by11.50% 
or 1.13 fold (p > 0.05).
The levels of serum calcium were significantly higher only 
in bone metastasis patients group as compared to control 
levels by 17.22% or 1.17 fold (p < 0.05).  The levels of serum 
calcium as compared to controls were lower in patients with 
primary bone cancer 2.95% or 0.03 fold (p > 0.05) and with 
benign bone tumors by 1.48% or 0.01 fold (p > 0.05).
The levels of serum phosphates were significantly higher 
in all investigated groups as compared with the control values 
(p < 0.05).  The levels of serum phosphate as compared with the 
control values were higher in the patients with primary bone 
cancer by 46.85% or 1.47 fold (p < 0.05), in patients with bone 
metastasis by 41.44% or 1.41 fold (p < 0.05) and with benign bone 
tumors by 52.25% by 1.52 fold (p < 0.05), see fig. 3.
The correlation analysis revealed significant positive cor-
relations between VEGF and CEA concentrations (r = 0.511, 
p = 0.007) and between VEGF and oxyproline concentrations 
(r = 0.315, p = 0.014) in the blood serum of the investigated 
patients.
Discussion
The bone is an unique and complex microenvironment 
that serves as a primary site for sarcomas [3] and a preferential 
secondary site for the metastasis of primary carcinomas such 
as breast, prostate and lung cancers [1, 4].  Little is known abo-
ut the role of angiogenesis and proangiogenic factors, such as 
VEGF, in the development and biologic activity of malignant 
bone tumors [7].  VEGF stimulates not only angiogenesis, 
but also osteoclastic bone resorption and osteoblastic bone 
formation, so it could have multiple effects [11].  The level 
of circulating VEGF in patients with different tumor types 
may be a predictive index of tumor status and prognosis [12]. 
Several clinical studies have found that many osteosarcoma 
patients with pulmonary metastasis had primary tumors with 
high levels of VEGF expression [13].  In a study of bone sarco-
ma however, serum levels of VEGF were elevated in contrast 
to tissue levels in Ewing sarcoma [8, 14].  In the process of 
bone metastasis formation, an increase in bone resorption is 
a crucial step prior to the invasion of the bone.  On the other 
hand a relation between tumor burden and circulating VEGF 
levels was shown by the rapid decrease of previously elevated 
concentrations of the compound after surgery [13-15].  Our 
data also show high levels of circulating VEGF in both primary 
bone tumors and bone metastasis.
Biomarkers are widely used in oncology for prognostic 
or predictive purposes.  An important area of biomarker 
use is the surveillance of cancer recurrence after treatment. 
However, for most solid tumors there are few blood-based 
biomarkers of the disease relapse, including CEA [9, 16]. 
CEA is synthesized during the development of the fetal gut, 
and is turned on in adults in case of intestinal carcinomas and 
other cancers [10].  For monitoring patients with metastatic 
disease during active therapy, CEA can be used in combination 
with diagnostic imaging [17].  The high levels of the CEA 
are predictive markers of metastasis into the axial skeleton, 
of multiple skeletal metastases and visceral metastasis [18]. 
Tumor markers such as CEA are useful as a screening test to 
distinguish skeletal metastasis of carcinoma from primary 
bone tumors or hematological malignancy from primary 
bone tumor [18].  CEA appears currently as the most useful 
biochemical marker for the prediction of the risk of recur-
rence of the disease and the assessment of the response to the 
treatment or it failure [19].
Bone is a living tissue and consists of appatite and various 
proteins that make it strong.  Secondary bone cancer can alter 
the bone structure so that calcium is released from the appatite 
into the bloodstream [20].  However, the release of calcium 
from living bone by tumor cells is mediated partially through 
stimulation of the endogenous bone-resorbing systems [21]. 
The development of the bone tumors lead to abnormalities of 
the regulation of the bone calcium and phosphate content by 
PTH that will induce disturbances in the bone and mineral 
metabolism [20].  Alterations in calcium and phosphate ba-
lance should be restored with bisphosphonates before starting 
the therapy of the bone tumors [7].  Physicians could monitor 
a patient’s calcium level over his or her lifetime and detect 
metastatic cancer in the early stages, when treatment would 
be more effective [22].
Oxyproline is produced by oxidation of proline [23].  It 
is one of the major collagen’s amino acids, which enables 
it as a marker that reflects the catabolism of this protein 
[24].  Oxyproline content which correlates with the rise in 
serum antioxidant activity is observed in some malignant 
tumors [25].
Our data show high levels in serum calcium, phosphates 
and oxyproline in bone metastasis.  In addition, high levels 
of both serum phosphorus and oxyproline were observed in 
primary bone cancer.  However, in benign bone tumor only 
high levels of serum phosphorus were observed.
Conclusions
Our results suggest that angiogenesis indices (VEGF) 
may be potential prognostic markers of bone tumors and 
may be a potential target for their therapy.  In addition, we 
can conclude that the calcium and phosphorus contents, in 
addition to VEGF, CEA and oxyproline levels, could be useful 
in prognosis and differentiation of the bone tumors.  Future 
studies in larger series are needed to confirm these data.
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Lipid Peroxidation and Enzymatic Antioxidants in Ulcerative Colitis
S. Turcan, V.-T. Dumbrava, L. Tofan-Scutaru, A. Peltec
Laboratory of Gastroenterology 
Nicolae Testemitanu State Medical and Pharmaceutical University, Chisinau
Abstract
Increased oxidative stress has been previously demonstrated in patients with inflammatory bowel disease.  But this phenomenon has not been 
analyzed in the course of ulcerative colitis (UC).  In this study we evaluated levels of malondialdehyde (the main product of lipid peroxidation), 
superoxide dismutase and catalase erythrocyte activities in 62 patients with active UC, in 22 patients after achievement of complete, endoscopic 
remission and in 52 control subjects.  Significant increase of malondialdehyde in patients with active disease in comparison with control 
subjects, demonstrated in this study, suggests the presence of enhanced oxidative stress in active UC.  Activation of enzymatic antioxidant 
system is characteristic of active UC, which is confirmed by an increase in superoxide dismutase and catalase erythrocyte activities in patients 
with active disease in comparison with control group.  There is no significant difference in malondialdehyde and catalase erythrocyte activity 
between patients in remission of UC and the control subjects.  The increase of conditional adaptive index in patients with active UC confirms 
large adaptive possibilities of enzymatic antioxidant system.  The normal levels of malondialdehyde and catalase can be proposed as markers of 
complete disease remission in UC.
Key words: ulcerative colitis, oxidative stress, lipid peroxidation, malondialdehyde, superoxide dismutase, catalase, adaptive index.
